Coronary
State-of-the-Art Paper
Current Status of Rotational Atherectomy

https://doi.org/10.1016/j.jcin.2013.12.196Get rights and content
Under an Elsevier user license
open archive

Rotational atherectomy facilitates percutaneous coronary intervention for complex de novo lesions with severe calcification. A strategy of routine rotational atherectomy has not, however, conferred reduction in restenosis or major adverse cardiac events. As it is technically demanding, rotational atherectomy is also uncommon. At this 25-year anniversary since the introduction of rotational atherectomy, we sought to review the current state-of-the-art in rotational atherectomy technique, safety, and efficacy data in the modern era of drug-eluting stents, strategies to prevent and manage complications, including slow-flow/no-reflow and burr entrapment, and appropriate use in the context of the broader evolution in the management of stable ischemic heart disease. Fundamental elements of optimal technique include use of a single burr with burr-to-artery ratio of 0.5 to 0.6-rotational speed of 140,000 to 150,000 rpm, gradual burr advancement using a pecking motion, short ablation runs of 15 to 20 s, and avoidance of decelerations >5,000 rpm. Combined with meticulous technique, optimal antiplatelet therapy, vasodilators, flush solution, and provisional use of atropine, temporary pacing, vasopressors, and mechanical support may prevent slow-flow/no-reflow, which in contemporary series is reported in 0.0% to 2.6% of cases. On the basis of the results of recent large clinical trials, a subset of patients with complex coronary artery disease previously assigned to rotational atherectomy may be directed instead to medical therapy alone or bypass surgery. For patients with de novo severely calcified lesions for which rotational atherectomy remains appropriate, referral centers of excellence are required.

Key Words

calcified lesions
complications
drug-eluting stents
rotational atherectomy

Abbreviations and Acronyms

BMS
bare-metal stent(s)
CABG
coronary artery bypass graft surgery
DES
drug-eluting stent(s)
ISR
in-stent restenosis
IVUS
intravascular ultrasound
MACE
major adverse cardiovascular events
MI
myocardial infarction
OCT
optical coherence tomography
PCI
percutaneous coronary intervention
RA
rotational atherectomy

Cited by (0)

Dr. Kini is on the Speakers' Bureau for the American College of Cardiology. Dr. Sharma is on the Speakers' Bureau for Abbott, Angioscore, Boston Scientific, Daiichi Sankyo, Inc./Eli Lilly and Company, and The Medicines Company. Dr. Tomey has reported that he has no relationships relevant to the contents of this paper to disclose.